Maria Pia Protti

List of Publications by Year
in descending order

58	3,513	186265 28	161849 54
papers	citations	h-index	g-index

59	59	59	4733
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nature Biotechnology, 1999, 17, 555-561.	17.5	703
2	Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. Journal of Experimental Medicine, 2011, 208, 469-478.	8.5	590
3	Melanoma Cells Present a MAGE-3 Epitope to CD4+ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11. Journal of Experimental Medicine, 1999, 189, 871-876.	8.5	204
4	Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. Science Advances, 2021, 7, .	10.3	157
5	The Nicotinic Acetylcholine Receptor: Structure and Autoimmune Pathology. Critical Reviews in Biochemistry and Molecular Biology, 1994, 29, 69-123.	5.2	134
6	Basophil Recruitment into Tumor-Draining Lymph Nodes Correlates with Th2 Inflammation and Reduced Survival in Pancreatic Cancer Patients. Cancer Research, 2016, 76, 1792-1803.	0.9	114
7	Myasthenia gravis: recognition of a human autoantigen at the molecular level. Trends in Immunology, 1993, 14, 363-368.	7.5	103
8	Carcinoembryonic Antigen-Specific but Not Antiviral CD4+ T Cell Immunity Is Impaired in Pancreatic Carcinoma Patients. Journal of Immunology, 2008, 181, 6595-6603.	0.8	97
9	Dendritic cell-derived IL-2 production is regulated by IL-15 in humans and in mice. Blood, 2005, 105, 697-702.	1.4	88
10	Identification of immunodominant regions among promiscuous HLA-DRâ€“restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. Blood, 2003, 101, 1038-1044.	1.4	82
11	Immune infiltrates as predictive markers of survival in pancreatic cancer patients. Frontiers in Physiology, 2013, 4, 210.	2.8	81
12	Immunodominant regions for T helper-cell sensitization on the human nicotinic receptor alpha subunit in myasthenia gravis.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 7792-7796.	7.1	70
13	Cross-talk within the tumor microenvironment mediates Th2-type inflammation in pancreatic cancer. OncoImmunology, 2012, 1, 89-91.	4.6	61
14	The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer. , 2019, 7, 45.		54
15	Tumor antigenâ€specific <scp>CD4</scp>⁺ T cells in cancer immunity: from antigen identification to tumor prognosis and development of therapeutic strategies. Tissue Antigens, 2014, 83, 237-246.	1.0	51
16	Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8⁺ and CD4⁺ T-cell responses with multiple specificities including a novel DR7-restricted epitope. OncoImmunology, 2016, 5, e1216290.	4.6	50
17	Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif. Molecular Immunology, 2006, 43, 1509-1518.	2.2	49
18	Epitopes on the beta subunit of human muscle acetylcholine receptor recognized by CD4+ cells of myasthenia gravis patients and healthy subjects.. Journal of Clinical Investigation, 1994, 93, 1020-1028.	8.2	48

#	Article	IF	Citations
19	In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells. European Journal of Immunology, 1994, 24, 2691-2698.	2.9	45
20	CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. Cancer Research, 2003, 63, 8481-6.	0.9	45
21	IFN-Î³ Produced by Human Papilloma Virus-18 E6-Specific CD4+ T Cells Predicts the Clinical Outcome after Surgery in Patients with High-Grade Cervical Lesions. Journal of Immunology, 2007, 179, 7176-7183.	0.8	42
22	T helper cell recognition of muscle acetylcholine receptor in myasthenia gravis. Epitopes on the gamma and delta subunits.. Journal of Clinical Investigation, 1993, 92, 1055-1067.	8.2	39
23	Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival. OncoImmunology, 2015, 4, e1005460.	4.6	37
24	T-Helper Epitopes on Human Nicotinic Acetylcholine Receptor in Myasthenia Gravis. Annals of the New York Academy of Sciences, 1993, 681, 198-218.	3.8	33
25	Dual Role of Inflammasome Adaptor ASC in Cancer. Frontiers in Cell and Developmental Biology, 2020, 8, 40.	3.7	33
26	T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFÎ± Expression and Empower Adoptive Cell Therapy for Solid Tumors. Cancer Research, 2017, 77, 658-671.	0.9	30
27	Constitutive expression of the heat shock protein 72 kDa in human melanoma cells. Cancer Letters, 1994, 85, 211-216.	7.2	29
28	Non-Redundant Role for IL-12 and IL-27 in Modulating Th2 Polarization of Carcinoembryonic Antigen Specific CD4 T Cells from Pancreatic Cancer Patients. PLoS ONE, 2009, 4, e7234.	2.5	29
29	Role of antigen-presenting cells in cross-priming of cytotoxic T lymphocytes by apoptotic cells. Journal of Leukocyte Biology, 1999, 66, 247-251.	3.3	28
30	Myasthenia gravis. CD4+ T epitopes on the embryonic gamma subunit of human muscle acetylcholine receptor.. Journal of Clinical Investigation, 1992, 90, 1558-1567.	8.2	26
31	Human Melanoma Cells Transfected with the B7-2 Co-Stimulatory Molecule Induce Tumor-Specific CD8⁺Cytotoxic T LymphocytesIn Vitro. Human Gene Therapy, 1998, 9, 1335-1344.	2.7	25
32	Tumor-derived factors affecting immune cells. Cytokine and Growth Factor Reviews, 2017, 36, 79-87.	7.2	25
33	B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma. OncoImmunology, 2020, 9, 1794359.	4.6	25
34	Cancer immunotherapy: synthetic and natural peptides in the balance. Trends in Immunology, 1999, 20, 457-462.	7.5	22
35	Thymic Stromal Lymphopoietin and Cancer: Th2-Dependent and -Independent Mechanisms. Frontiers in Immunology, 2020, 11, 2088.	4.8	22
36	Identification of Novel Subdominant Epitopes on the Carcinoembryonic Antigen Recognized by CD4+ T Cells of Lung Cancer Patients. Journal of Immunology, 2006, 176, 5093-5099.	0.8	20

#	Article	IF	Citations
37	Serological Immunoreactivity against Colon Cancer Proteome Varies upon Disease Progression. Journal of Proteome Research, 2008, 7, 504-514.	3.7	20
38	Blockade of the Fas-triggered intracellular signaling pathway in human melanomas is circumvented by cytotoxic lymphocytes. , 1999, 81, 573-579.		19
39	Generation of functional HLA-DR*1101 tetramers receptive for loading with pathogen- or tumour-derived synthetic peptides. BMC Immunology, 2005, 6, 24.	2.2	18
40	T-Cell Receptor-Mediated Cross-Allergenicity. International Archives of Allergy and Immunology, 2004, 135, 296-305.	2.1	17
41	Molecular mimicry among human autoantigens. Trends in Immunology, 1991, 12, 46-47.	7.5	16
42	High-throughput Screening of Human Tumor Antigenâ€“specific CD4 T Cells, Including Neoantigen-reactive T Cells. Clinical Cancer Research, 2019, 25, 4320-4331.	7.0	15
43	CD4⁺ T cells against human papillomavirusâ€18 E7 in patients with highâ€grade cervical lesions associate with the absence of the virus in the cervix. Immunology, 2010, 131, 89-98.	4.4	13
44	Non-redundant roles for Th17 and Th22 cells in multiple myeloma clinical correlates. OncoImmunology, 2016, 5, e1093278.	4.6	13
45	TCR VÎ² Usage by Acetylcholine Receptor-Specific CD4+T Cells in Myasthenia Gravis. Journal of Autoimmunity, 1997, 10, 203-217.	6.5	12
46	CD4+ T cell immunity against the human papillomavirus-18 E6 transforming protein in healthy donors: identification of promiscuous naturally processed epitopes. European Journal of Immunology, 2005, 35, 806-815.	2.9	12
47	Endosomal Proteases Influence the Repertoire of MAGE-A3 Epitopes Recognized In vivo by CD4+ T Cells. Cancer Research, 2008, 68, 1555-1562.	0.9	12
48	Flow cytometry data mining by cytoChain identifiesÂdeterminants of exhaustion and stemness in TCRâ€engineered T cells. European Journal of Immunology, 2021, 51, 1992-2005.	2.9	10
49	MAGE-A3161â€“175 contains an HLA-DRÎ²4 restricted natural epitope poorly formed through indirect presentation by dendritic cells. Cancer Immunology, Immunotherapy, 2007, 57, 207-215.	4.2	9
50	Immunomodulatory Drugs in the Context of Autologous Hematopoietic Stem Cell Transplantation Associate With Reduced Pro-tumor T Cell Subsets in Multiple Myeloma. Frontiers in Immunology, 2018, 9, 3171.	4.8	9
51	Immunotherapy: natural versus synthetic peptides. Trends in Immunology, 1998, 19, 98.	7.5	6
52	Peptidome from Renal Cell Carcinoma Contains Antigens Recognized by CD4+ T Cells and Shared among Tumors of Different Histology. Clinical Cancer Research, 2006, 12, 4949-4957.	7.0	6
53	The CD4⁺ Tâ€cell epitopeâ€binding register is a critical parameter when generating functional HLAâ€DR tetramers with promiscuous peptides. European Journal of Immunology, 2010, 40, 1603-1616.	2.9	6
54	Estimating Point and Interval Frequency of Antigen-Specific CD4+ T Cells Based on Short In Vitro Expansion and Improved Poisson Distribution Analysis. PLoS ONE, 2012, 7, e42340.	2.5	4

#	Article	IF	Citations
55	Acetylcholine Receptor-specific CD4+ T Cells in Myasthenia Gravis Patients Have Individual, but Restricted TCR Vbeta Usagea. Annals of the New York Academy of Sciences, 1998, 841, 324-328.	3.8	3
56	Circulating Chromogranin A Is Cleaved Into Vasoregulatory Fragments in Patients With Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology, 2020, 10, 613582.	2.8	2
57	Quantitative and Qualitative Analysis of Tumor-Associated CD4+ T Cells. Methods in Molecular Biology, 2016, 1393, 37-51.	0.9	0
58	Autoimmunity Against the Nicotinic Acetylcholine Receptor and the Presynaptic Calcium Channel at the Neuromuscular Junction. E&M Endocrinology and Metabolism, 1994, , 151-189.	0.1	0